FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597949649> ?p ?o ?g. }

• W2597949649 endingPage "625" @default.
• W2597949649 startingPage "619" @default.
• W2597949649 abstract "A prospective observational multicenter trial was carried out to assess the incidence, pattern, and prognostic factors of radiation-induced emesis (RIE), and evaluate the use of antiemetic drugs in radiation oncology clinical practice.Fifty-one Italian radiation oncology centers took part in this trial. The accrual lasted 2 consecutive weeks, only patients starting radiotherapy in this period were enrolled. Exclusion criteria were age under 18 years, and concomitant chemotherapy. Evaluation was based on diary cards filled in daily by patients during radiotherapy and 1 week after stopping it. Diary cards recorded the intensity of nausea and any episode of vomiting and retching. Prophylactic and symptomatic antiemetic drug prescriptions were also registered.Nine hundred thirty-four patients entered the trial, and 914 were evaluable. Irradiated sites were: breast in 211 patients, pelvis in 210 patients, head and neck in 136 patients, thorax in 129 patients, brain in 52 patients, upper abdomen in 42 patients, skin and/or extremities in 37 patients, and other sites in 97 patients. Vomiting and nausea occurred in 17.1% and 37.3% of patients, respectively, and 38.7 % patients had both vomiting and nausea. At multifactorial analysis, the only patient-related risk factor that was statistically significant was represented by previous experience with cancer chemotherapy. Moreover, two radiotherapy (RT)-related factors were significant risk factors for RIE, the irradiated site and field size. In fact, a statistically significant higher percentage of RIE was registered in upper abdomen RT and RT fields > 400 cm2. Although nonstatistically significant, patients receiving RT to the thorax and head and neck presented a higher incidence of RIE. Only a minority (14%) of patients receiving RT were given an antiemetic drug, and the prescriptions were more often symptomatic than prophylactic (9% vs. 5%, respectively). Different compounds and a wide range of doses and schedules were used; however, there is some evidence from our data that in spite of antiemetic prophylaxis, 46% of patients had vomiting, and 58% had nausea. The majority (93%) of the prophylactic group received oral 5-hydroxytriptamine receptor (5-HT3) antagonist (8 mg/day, 7 days/week). In the symptomatic group, 54% and 41% patients received 5-HT3 antagonists and metoclopramide, respectively. At multivariate analysis, no patient- or RT-related risk factor for RIE was found to influence significantly the prophylactic or symptomatic use of antiemetics.Our study provided useful data on epidemiology and characteristics of RIE. Previous chemotherapy, field size, and irradiated site (upper abdomen) were the only significant prognostic factors of RIE. A remarkable incidence of RIE was found in patients submitted to thoracic and head and neck RT. With this background of knowledge, it will be possible to better plan further studies on this important problem. Moreover, the low rate of antiemetics use and the wide variety of doses and schedules employed suggest the need to reinforce the evidence based approach to identify the best antiemetic approach to RIE." @default.
• W2597949649 created "2017-04-07" @default.
• W2597949649 creator A5000564878 @default.
• W2597949649 creator A5000862499 @default.
• W2597949649 creator A5001259661 @default.
• W2597949649 creator A5003168970 @default.
• W2597949649 creator A5004332760 @default.
• W2597949649 creator A5005769752 @default.
• W2597949649 creator A5006043720 @default.
• W2597949649 creator A5007240762 @default.
• W2597949649 creator A5010118679 @default.
• W2597949649 creator A5011666981 @default.
• W2597949649 creator A5012875014 @default.
• W2597949649 creator A5013088855 @default.
• W2597949649 creator A5013396009 @default.
• W2597949649 creator A5014783044 @default.
• W2597949649 creator A5014935150 @default.
• W2597949649 creator A5015515380 @default.
• W2597949649 creator A5015536216 @default.
• W2597949649 creator A5016277183 @default.
• W2597949649 creator A5016279522 @default.
• W2597949649 creator A5018832451 @default.
• W2597949649 creator A5019010187 @default.
• W2597949649 creator A5019358863 @default.
• W2597949649 creator A5020388682 @default.
• W2597949649 creator A5022985047 @default.
• W2597949649 creator A5023455069 @default.
• W2597949649 creator A5023893215 @default.
• W2597949649 creator A5024041877 @default.
• W2597949649 creator A5024427148 @default.
• W2597949649 creator A5026459926 @default.
• W2597949649 creator A5028368824 @default.
• W2597949649 creator A5031999545 @default.
• W2597949649 creator A5033968769 @default.
• W2597949649 creator A5036313704 @default.
• W2597949649 creator A5039073682 @default.
• W2597949649 creator A5041808611 @default.
• W2597949649 creator A5042502380 @default.
• W2597949649 creator A5044885644 @default.
• W2597949649 creator A5045181526 @default.
• W2597949649 creator A5045448518 @default.
• W2597949649 creator A5046587638 @default.
• W2597949649 creator A5047915463 @default.
• W2597949649 creator A5048368145 @default.
• W2597949649 creator A5048805839 @default.
• W2597949649 creator A5049047442 @default.
• W2597949649 creator A5049202618 @default.
• W2597949649 creator A5050465350 @default.
• W2597949649 creator A5050865051 @default.
• W2597949649 creator A5052234354 @default.
• W2597949649 creator A5052901577 @default.
• W2597949649 creator A5053972376 @default.
• W2597949649 creator A5055318975 @default.
• W2597949649 creator A5055888140 @default.
• W2597949649 creator A5057809323 @default.
• W2597949649 creator A5058026371 @default.
• W2597949649 creator A5060189508 @default.
• W2597949649 creator A5060312538 @default.
• W2597949649 creator A5060724687 @default.
• W2597949649 creator A5066165482 @default.
• W2597949649 creator A5066586507 @default.
• W2597949649 creator A5066733539 @default.
• W2597949649 creator A5067433792 @default.
• W2597949649 creator A5068481114 @default.
• W2597949649 creator A5069535579 @default.
• W2597949649 creator A5070190573 @default.
• W2597949649 creator A5072169960 @default.
• W2597949649 creator A5072530854 @default.
• W2597949649 creator A5072558847 @default.
• W2597949649 creator A5077596666 @default.
• W2597949649 creator A5078826342 @default.
• W2597949649 creator A5080589060 @default.
• W2597949649 creator A5081850635 @default.
• W2597949649 creator A5084484357 @default.
• W2597949649 creator A5087640593 @default.
• W2597949649 creator A5088257259 @default.
• W2597949649 creator A5088624316 @default.
• W2597949649 creator A5089450570 @default.
• W2597949649 creator A5089997611 @default.
• W2597949649 creator A5090813898 @default.
• W2597949649 date "1999-06-01" @default.
• W2597949649 modified "2023-10-13" @default.
• W2597949649 title "Radiation-induced emesis: a prospective observational multicenter Italian trial" @default.
• W2597949649 cites W1773918498 @default.
• W2597949649 cites W1976238589 @default.
• W2597949649 cites W1977616103 @default.
• W2597949649 cites W1980266837 @default.
• W2597949649 cites W1982078999 @default.
• W2597949649 cites W1986673918 @default.
• W2597949649 cites W2019040902 @default.
• W2597949649 cites W2053340971 @default.
• W2597949649 cites W2065746078 @default.
• W2597949649 cites W2074080420 @default.
• W2597949649 cites W2075737326 @default.
• W2597949649 cites W2079878418 @default.
• W2597949649 cites W2083985425 @default.
• W2597949649 cites W2090056202 @default.
• W2597949649 cites W2118312302 @default.

• next